CompoAtlas

Shred Matrix

En vente sur le marché américain (selon le DSLD)

MusclePharm, food supplement from the US market

Shred Matrix (MusclePharm), a food supplement without a usable barcode in DSLD, is described by its US market label. If sold in France, it would be subject to 4 points of French or European regulation, detailed below. Doses of niacine are not compared: their US units depend on the form. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
MusclePharm
Barcode
Not provided or invalid in DSLD
Form
Capsule
One serving
3 capsules
Servings
up to 2 servings per day
Other ingredients (in English, as written)
Gelatin, Magnesium Stearate, Microcrystalline Cellulose
Ingredient (as written, in English)CategoryPer serving
NiacinVitamin3 mg
BiotinVitamin150 µg
Pantothenic AcidVitamin3 mg
MagnesiumMineral3.5 mg
Olive leaf extractPlant1 mg
ChromiumMineral100 µg
8 Stage Weight Loss Proprietary BlendBlend2437.5 mg
Stages 1 & 2: Energy & Fat MetabolismBlendnot stated
Guarana seed extractPlantnot stated
Caffeine AnhydrousOther substance150 mg
Green Tea Extract (Camellia sinensis)Plantnot stated
Suma Extract (Hebanthe eriantha)Plantnot stated
Saw Palmetto (Serenoa repens)Plantnot stated
Yerba Mate (Ilex paraguariensis)Plantnot stated
Fo-Ti (Reynoutria multiflora)Plantnot stated
Eleuthero (Eleutherococcus senticosus)Plantnot stated
Cayenne (Capsicum annuum)Plantnot stated
Yohimbine HClOther substancenot stated
Stages 3 & 4: Appetite Balancing & Weight Management ControlBlendnot stated
Stage 5: Anti-Stress Mood Balancing MatrixBlendnot stated
Stage 6: Brain Power MatrixBlendnot stated
Stage 7: Diuretic ComplexBlendnot stated
Stage 8: Sugar Stop(TM) & Enzyme Aid MatrixBlendnot stated

Other versions of this label

The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Saw Palmetto
    Read the warning, when it applies and the studies cited

    SAW PALMETTO – SERENOA REPENS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All subpopulations.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Adult males only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Adult females only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Condition of application: Adult females only.

    Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

  • Eleuthero
    Read the warning, when it applies and the studies cited

    ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS

    Route of administration: Oral (ESCOP 2003; Bradley 1992)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 31 October 2025

  • Cayenne
    Read the warning, when it applies and the studies cited

    CAYENNE - CAPSICUM ANNUUM Oral

    Cautions and warnings

    Condition of application: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Cautions and warnings

    Condition of application: All products.

    For external use only (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 March 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : MusclePharm

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2013. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line